Endocannabinoid system: Potential novel targets for treatment of schizophrenia
Accumulating epidemiological evidences suggest that cannabis use during adolescence is a potential environmental risk for the development of psychosis, including schizophrenia. Consistently, clinical and preclinical studies, using pharmacological approaches and genetically engineered animals to targ...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2013-05-01
|
| Series: | Neurobiology of Disease |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S096999611200383X |
| _version_ | 1819120097255489536 |
|---|---|
| author | Atsushi Saito Michael D.L. Ballinger Mikhail V. Pletnikov Dean F. Wong Atsushi Kamiya |
| author_facet | Atsushi Saito Michael D.L. Ballinger Mikhail V. Pletnikov Dean F. Wong Atsushi Kamiya |
| author_sort | Atsushi Saito |
| collection | DOAJ |
| description | Accumulating epidemiological evidences suggest that cannabis use during adolescence is a potential environmental risk for the development of psychosis, including schizophrenia. Consistently, clinical and preclinical studies, using pharmacological approaches and genetically engineered animals to target endocannabinoid signaling, reveal the multiple varieties of endocannabinoid system-mediated human and animal behaviors, including cognition and emotion. Recently, there has been substantial progress in understanding the molecular mechanisms of the endocannabinoid system for synaptic communications in the central nervous system. Furthermore, the impact of endocannabinoid signaling on diverse cellular processes during brain development has emerged. Thus, although schizophrenia has etiological complexities, including genetic heterogeneities and multiple environmental factors, it now becomes crucial to explore molecular pathways of convergence of genetic risk factors and endocannabinoid signaling, which may provide us with clues to find novel targets for therapeutic intervention. In this review, epidemiological, clinical, and pathological evidences on the role of the endocannabinoid system in the pathophysiologies of schizophrenia will be presented. We will also make a brief overview of the recent progress in understanding molecular mechanisms of the endocannabinoid system for brain development and function, with particular focus on cannabinoid receptor type 1 (CB1R)-mediated cascade, the most well-characterized cannabinoid receptor. Lastly, we will discuss the potential of the endocannabinoid system in finding novel therapeutic targets for prevention and treatment of schizophrenia. |
| first_indexed | 2024-12-22T06:15:15Z |
| format | Article |
| id | doaj.art-961e4b6277e44cd48b8ef0c19996eaf2 |
| institution | Directory Open Access Journal |
| issn | 1095-953X |
| language | English |
| last_indexed | 2024-12-22T06:15:15Z |
| publishDate | 2013-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Neurobiology of Disease |
| spelling | doaj.art-961e4b6277e44cd48b8ef0c19996eaf22022-12-21T18:36:06ZengElsevierNeurobiology of Disease1095-953X2013-05-01531017Endocannabinoid system: Potential novel targets for treatment of schizophreniaAtsushi Saito0Michael D.L. Ballinger1Mikhail V. Pletnikov2Dean F. Wong3Atsushi Kamiya4Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Biological Psychiatry and Neuroscience, Dokkyo Medical University School of Medicine, Mibu, JapanDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USADepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USADepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Division of Nuclear Medicine, Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USADepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Corresponding author at: Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Meyer 3-146, Baltimore, MD 21287, USA.Accumulating epidemiological evidences suggest that cannabis use during adolescence is a potential environmental risk for the development of psychosis, including schizophrenia. Consistently, clinical and preclinical studies, using pharmacological approaches and genetically engineered animals to target endocannabinoid signaling, reveal the multiple varieties of endocannabinoid system-mediated human and animal behaviors, including cognition and emotion. Recently, there has been substantial progress in understanding the molecular mechanisms of the endocannabinoid system for synaptic communications in the central nervous system. Furthermore, the impact of endocannabinoid signaling on diverse cellular processes during brain development has emerged. Thus, although schizophrenia has etiological complexities, including genetic heterogeneities and multiple environmental factors, it now becomes crucial to explore molecular pathways of convergence of genetic risk factors and endocannabinoid signaling, which may provide us with clues to find novel targets for therapeutic intervention. In this review, epidemiological, clinical, and pathological evidences on the role of the endocannabinoid system in the pathophysiologies of schizophrenia will be presented. We will also make a brief overview of the recent progress in understanding molecular mechanisms of the endocannabinoid system for brain development and function, with particular focus on cannabinoid receptor type 1 (CB1R)-mediated cascade, the most well-characterized cannabinoid receptor. Lastly, we will discuss the potential of the endocannabinoid system in finding novel therapeutic targets for prevention and treatment of schizophrenia.http://www.sciencedirect.com/science/article/pii/S096999611200383XCannabisEndocannabinoid systemSchizophreniaGenetic risk factorEnvironmental factor |
| spellingShingle | Atsushi Saito Michael D.L. Ballinger Mikhail V. Pletnikov Dean F. Wong Atsushi Kamiya Endocannabinoid system: Potential novel targets for treatment of schizophrenia Neurobiology of Disease Cannabis Endocannabinoid system Schizophrenia Genetic risk factor Environmental factor |
| title | Endocannabinoid system: Potential novel targets for treatment of schizophrenia |
| title_full | Endocannabinoid system: Potential novel targets for treatment of schizophrenia |
| title_fullStr | Endocannabinoid system: Potential novel targets for treatment of schizophrenia |
| title_full_unstemmed | Endocannabinoid system: Potential novel targets for treatment of schizophrenia |
| title_short | Endocannabinoid system: Potential novel targets for treatment of schizophrenia |
| title_sort | endocannabinoid system potential novel targets for treatment of schizophrenia |
| topic | Cannabis Endocannabinoid system Schizophrenia Genetic risk factor Environmental factor |
| url | http://www.sciencedirect.com/science/article/pii/S096999611200383X |
| work_keys_str_mv | AT atsushisaito endocannabinoidsystempotentialnoveltargetsfortreatmentofschizophrenia AT michaeldlballinger endocannabinoidsystempotentialnoveltargetsfortreatmentofschizophrenia AT mikhailvpletnikov endocannabinoidsystempotentialnoveltargetsfortreatmentofschizophrenia AT deanfwong endocannabinoidsystempotentialnoveltargetsfortreatmentofschizophrenia AT atsushikamiya endocannabinoidsystempotentialnoveltargetsfortreatmentofschizophrenia |